Clinical Trial Protocol Registry

Trial information

A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers

Protocol number:
Hoffmann-La Roche
Company division:
Product name:
Official Scientific Title:
A single center, randomized, double-blind, parallel-design study to investigate the safety and tolerability of RO4995819 in combination with citalopram following oral administration in healthy volunteers
Brief summary:
This randomized, double-blind, parallel-arm study will assess the safety and tolerability of RO4995819 in combination with citalopram in healthy volunteers. Subjects will receive citalopram orally on Days 1-9 and be randomized to receive either RO4995819 orally or placebo in combination with citalopram on Days 10-16. Safety follow-up will be up to Day 58. Target sample size is 32.
Study phase:
Study type:
Interventional; Other; Randomized; Double Blind; Parallel; Safety study
  • Healthy Volunteer
Primary outcome:
  1. Safety: Incidence of adverse events Time frame: up to 58 days
Key secondary outcomes:
  1. Effect of multiple doses of RO4995819 on the pharmacokinetics (Cmax, AUC) of citalopram Time frame: 17 days
  2. Effect of genetic variants of drug metabolism on pharmacokinetics (Cmax, AUC) of RO4995819 in combination with citalopram Time frame: up to 58 days
Inclusion criteria:
  • Adult healthy male or female subjects, 18 to 65 years of age inclusive (healthy status defined as absence of evidence of any active or chronic disease)
  • Body mass index (BMI) 18.0 to 30.0 kg/m2 inclusive
  • Female subjects who are not either surgically sterile or post-menopausal must commit to using a barrier form of contraception in addition to either an intrauterine device or hormonal contraception until at least 5 months after the last dose of study drug
  • Male subjects must use a barrier method of contraception throughout the study and for up to 5 months after the last dose of study drug (applies also to surgically sterilized males)
  • Willing not to participate in any other clinical trial with an investigational drug for at least 5 months following the last dose of study drug
Exclusion criteria:
  • Pregnant or lactating females
  • Suspicion of regular consumption of drug of abuse or positive test for alcohol on Day -2
  • Hepatitis B, hepatitis C or HIV infection
  • Smokers of >5 cigarettes or equivalent tobacco intake per day
  • Any confirmed allergic reaction against any drug, or multiple allergies (non-active hay fever is acceptable)
  • Participation in an investigational drug or device study within 3 months prior to dosing
Males or Females
Age limits:
Min: 18 years Max: 65 years
Accepts healthy volunteers:
Anticipated start date:
May, 2011
Trial registration date:
Date last updated:
This trial was conducted at the following locations:

Link to trial result

For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.

  • Go on the URL link- and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.

Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.

For US or global trials with US and Canada sites only, please contact the Trial Information Support Line (TISL)